Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
71 studies found for:    Open Studies | "Conjunctivitis"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Not yet recruiting Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640;   Drug: Placebo
2 Not yet recruiting Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
3 Recruiting Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
Condition: Bacterial Conjunctivitis
Interventions: Drug: Vancomycin 1.1%;   Drug: Placebo
4 Not yet recruiting Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
Condition: Adenoviral Conjunctivitis
Interventions: Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
5 Recruiting Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients
Conditions: Epiphora;   Conjunctivitis
Interventions: Device: Perforated Punctal plugs;   Procedure: Crawford tube insertion;   Device: Crawford lacrimal tube
6 Recruiting Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Condition: Conjunctivitis, Allergic
Intervention: Drug: Alcaftadine Ophthalmic Solution 0.25%
7 Recruiting Reducing Adenoviral Patient Infected Days
Conditions: Conjunctivitis;   Adenoviral Conjunctivitis
Interventions: Drug: Betadine 5%;   Drug: Artificial Tears
8 Not yet recruiting Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
Condition: Adenoviral Conjunctivitis
Interventions: Drug: Iota-Carrageenan;   Drug: Carmellose
9 Recruiting Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
Conditions: Allergic Conjunctivitis;   Allergic Rhinitis
Interventions: Biological: Dose Level 1: Short and Tall Ragweed Mix;   Biological: Dose Level 2: Short and Tall Ragweed Mix;   Biological: Placebo: Saline with 0.4% Phenol
10 Recruiting Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
Condition: Allergy
Intervention: Drug: Oralair
11 Not yet recruiting A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
Conditions: Allergic Rhinitis;   Allergic Conjunctivitis
Interventions: Biological: modified allergen extract;   Biological: Placebo
12 Recruiting Seasonal Differences in Nasal Mucus Proteome and Impact of Immunotherapy
Condition: Allergic Rhinoconjunctivitis
Intervention: Biological: Immunotherapy
13 Recruiting Efficacy and Safety of LAIS® Mites Sublingual Tablets
Condition: Allergic Conditions
Intervention: Drug: LAIS®
14 Recruiting Topical Tacrolimus in Vernal Keratoconjunctivitis
Condition: Vernal Keratoconjunctivitis
Intervention: Drug: Topical tacrolimus
15 Recruiting Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis
Condition: Hay Fever
Interventions: Biological: Placebo solution;   Biological: gpASIT+TM
16 Recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MM09 Mannosylated 5.000 subcutaneous;   Biological: MM09 Mannosylated 10.000 subcutaneous;   Biological: MM09 Mannosylated 30.000 subcutaneous;   Biological: MM09 Mannosylated 50.000 subcutaneous;   Biological: MM09 Mannosylated 5.000 sublingual;   Biological: MM09 Mannosylated 10.000 sublingual;   Biological: MM09 Mannosylated 30.000 sublingual;   Biological: MM09 Mannosylated 50.000 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
17 Recruiting Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Conditions: Rhinitis;   Rhinoconjunctivitis
Interventions: Biological: MG56 Mannosylated 60 subcutaneous;   Biological: MG56 Mannosylated 100 subcutaneous;   Biological: MG56 Mannosylated 300 subcutaneous;   Biological: MG56 Mannosylated 500 subcutaneous;   Biological: MG56 Mannosylated 60 sublingual;   Biological: MG56 Mannosylated 100 sublingual;   Biological: MG56 Mannosylated 300 sublingual;   Biological: MG56 Mannosylated 500 sublingual;   Biological: Subcutaneous placebo;   Biological: Sublingual placebo
18 Recruiting Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
Conditions: Rhinitis;   Rhinoconjunctivitis;   Asthma
Interventions: Biological: DP/MG/14-1;   Biological: DP/MG/14-2
19 Recruiting Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice
Conditions: Allergic Rhinitis;   Rhinoconjunctivitis;   Asthma
Intervention: Biological: Allergovac Poliplus
20 Recruiting Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.